189 related articles for article (PubMed ID: 30005936)
41. Cabozantinib and nivolumab for renal cell carcinoma.
Worley L
Lancet Oncol; 2015 Nov; 16(15):e531. PubMed ID: 26481805
[No Abstract] [Full Text] [Related]
42. An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC).
D'Angelo A; Bagby S; Di Pierro G; Chirra M; Nobili S; Mini E; Villari D; Roviello G
Crit Rev Oncol Hematol; 2020 May; 149():102921. PubMed ID: 32172222
[TBL] [Abstract][Full Text] [Related]
43. Editorial comment.
Rini BI; Shah SN
Urology; 2010 May; 75(5):1114-5; author reply 1115. PubMed ID: 20451727
[No Abstract] [Full Text] [Related]
44. Editorial comment.
Vaishampayan U
Urology; 2010 May; 75(5):1114; author reply 1115. PubMed ID: 20451726
[No Abstract] [Full Text] [Related]
45. Hand-foot skin reaction with primarily dorsal involvement in a patient with metastatic renal cell carcinoma on cabozantinib.
Goyal A; Jacobsen AA; O'Leary D; Watson A; Luikart S; Gaddis KJ
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941722
[TBL] [Abstract][Full Text] [Related]
46. Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy.
Thibault F; Billemont B; Rixe O
J Neurooncol; 2008 Jan; 86(2):243-4. PubMed ID: 17634858
[No Abstract] [Full Text] [Related]
47. Asymptomatic stroke is an underestimated side effect of cabozantinib.
Bronnimann C; Sibon I; Ravaud A; Gross-Goupil M
Rev Neurol (Paris); 2019 Jun; 175(6):409-410. PubMed ID: 31056194
[No Abstract] [Full Text] [Related]
48. Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region.
Nieder C; Syed MA; Dalhaug A; Pawinski A; Norum J
Med Oncol; 2017 Sep; 34(9):149. PubMed ID: 28748331
[TBL] [Abstract][Full Text] [Related]
49. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
Amzal B; Fu S; Meng J; Lister J; Karcher H
PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
[TBL] [Abstract][Full Text] [Related]
50. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Choueiri TK; Escudier B; Powles T; Mainwaring PN; Rini BI; Donskov F; Hammers H; Hutson TE; Lee JL; Peltola K; Roth BJ; Bjarnason GA; Géczi L; Keam B; Maroto P; Heng DY; Schmidinger M; Kantoff PW; Borgman-Hagey A; Hessel C; Scheffold C; Schwab GM; Tannir NM; Motzer RJ;
N Engl J Med; 2015 Nov; 373(19):1814-23. PubMed ID: 26406150
[TBL] [Abstract][Full Text] [Related]
51. Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation.
Li Y; Shen Y; Zhu Z; Wen H; Feng C
Cancer Med; 2020 Aug; 9(16):6020-6029. PubMed ID: 32628820
[TBL] [Abstract][Full Text] [Related]
52. Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison.
Porta C; Szczylik C; Casciano R; Fu S; Amzal B; Lister J; Karcher H; Meng J; Neumann M; Dinet J
Crit Rev Oncol Hematol; 2019 Jul; 139():143-148. PubMed ID: 30401604
[TBL] [Abstract][Full Text] [Related]
53. Good tolerability, long-term survival and easy management of side effects in a patient with metastatic renal cell carcinoma treated with pazopanib.
Frascaroli M; Di Cesare P
Tumori; 2014; 100(6):e301-4. PubMed ID: 25688516
[TBL] [Abstract][Full Text] [Related]
54. Kidney cancer: CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.
Thoma C
Nat Rev Clin Oncol; 2015 Nov; 12(11):621. PubMed ID: 26462125
[No Abstract] [Full Text] [Related]
55. CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.
Thoma C
Nat Rev Urol; 2015 Dec; 12(12):651. PubMed ID: 26458750
[No Abstract] [Full Text] [Related]
56. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
[TBL] [Abstract][Full Text] [Related]
57. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.
Zhao H; Nolley R; Chan AMW; Rankin EB; Peehl DM
Cancer Biol Ther; 2017 Nov; 18(11):863-871. PubMed ID: 27715452
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment.
Maksimovic O; Schraml C; Hartmann JT; Bitzer M; Claussen CD; Pintoffl J; Horger M
AJR Am J Roentgenol; 2010 Jan; 194(1):5-14. PubMed ID: 20028898
[TBL] [Abstract][Full Text] [Related]
59. [Tyrosine kinase inhibitor as adjuvant treatment of renal cell carcinoma: 1 versus 3].
Penel N
Bull Cancer; 2017 Sep; 104(9):705-706. PubMed ID: 28760312
[No Abstract] [Full Text] [Related]
60. Biomarkers in personalised treatment of renal-cell carcinoma.
Shariat SF; Xylinas E
Lancet Oncol; 2012 Aug; 13(8):751-2. PubMed ID: 22759479
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]